Group One Trading
PLX icon

Group One Trading’s Protalix BioTherapeutics PLX Stock Holding History

Group One Trading’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.2K Buy
+14,400
New +$35.7K ﹤0.01% 5627
2025
Q4 		– Sell
-4,600
Closed -$10.2K – 8929
2025
Q3 		$10.2K Buy
4,600
+4,300
+1,433% +$7K ﹤0.01% 7151
2025
Q2 		$444 Sell
300
-1,100
-79% -$2.25K ﹤0.01% 7677
2025
Q1 		$3.58K Sell
1,400
-600
-30% -$1.43K ﹤0.01% 6783
2024
Q4 		$3.76K Buy
+2,000
New +$2.83K ﹤0.01% 6531
2024
Q3 		– Sell
-3,400
Closed -$3.98K – 7203
2024
Q2 		$3.98K Sell
3,400
-2,100
-38% -$2.48K ﹤0.01% 6042
2024
Q1 		$6.93K Sell
5,500
-265,400
-98% -$396K ﹤0.01% 6050
2023
Q4 		$482K Sell
270,900
-209,100
-44% -$325K ﹤0.01% 3104
2023
Q3 		$797K Sell
480,000
-192,600
-29% -$346K ﹤0.01% 2486
2023
Q2 		$1.35M Buy
672,600
+69,700
+12% +$166K ﹤0.01% 2074
2023
Q1 		$1.27M Buy
602,900
+325,600
+117% +$571K ﹤0.01% 1936
2022
Q4 		$380K Sell
277,300
-76,000
-22% -$83.4K ﹤0.01% 3297
2022
Q3 		$368K Sell
353,300
-281,300
-44% -$312K ﹤0.01% 3533
2022
Q2 		$692K Buy
634,600
+468,600
+282% +$548K ﹤0.01% 3122
2022
Q1 		$176K Buy
166,000
+155,200
+1,437% +$142K ﹤0.01% 4931
2021
Q4 		$9K Sell
10,800
-218,700
-95% -$229K ﹤0.01% 7411
2021
Q3 		$305K Sell
229,500
-99,300
-30% -$151K ﹤0.01% 4731
2021
Q2 		$628K Buy
328,800
+266,500
+428% +$917K ﹤0.01% 3965
2021
Q1 		$278K Buy
62,300
+46,600
+297% +$217K ﹤0.01% 4664
2020
Q4 		$57K Sell
15,700
-62,600
-80% -$224K ﹤0.01% 4931
2020
Q3 		$303K Buy
78,300
+1,200
+2% +$4.34K ﹤0.01% 3313
2020
Q2 		$292K Buy
+77,100
New +$264K ﹤0.01% 3072
2018
Q3 		– Sell
-3,820
Closed -$16K – 5526
2018
Q2 		$16K Sell
3,820
-30
-0.8% -$133 ﹤0.01% 4459
2018
Q1 		$21K Sell
3,850
-8,960
-70% -$58.9K ﹤0.01% 4071
2017
Q4 		$85K Buy
+12,810
New +$86.4K ﹤0.01% 3446
2017
Q3 		– Sell
-7,750
Closed -$65K – 5079
2017
Q2 		$65K Buy
7,750
+2,750
+55% +$25.8K ﹤0.01% 3366
2017
Q1 		$68K Buy
+5,000
New +$45K ﹤0.01% 3218
2015
Q4 		– Sell
-1,000
Closed -$12K – 5011
2015
Q3 		$12K Sell
1,000
-5,230
-84% -$83.1K ﹤0.01% 4233
2015
Q2 		$121K Buy
6,230
+3,960
+174% +$82.2K ﹤0.01% 2930
2015
Q1 		$40K Buy
+2,270
New +$44.4K ﹤0.01% 3491
2014
Q4 		– Sell
-80
Closed -$2K – 5192
2014
Q3 		$2K Sell
80
-130
-62% -$3.75K ﹤0.01% 4935
2014
Q2 		$8K Buy
+210
New +$8.47K ﹤0.01% 4600
2013
Q3 		– Sell
-710
Closed -$35K – 5504
2013
Q2 		$35K Buy
+710
New +$37.7K ﹤0.01% 3725

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Group One Trading's PLX Position: Q1 2026 in Review

Group One Trading opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 13,222 shares worth $28.7K. The stake represents ﹤0.01% of the portfolio and ranks #5703 among its holdings. This is a return to the name: Group One Trading previously reported a position in PLX as recently as Q4 2024.

Group One Trading first reported a position in PLX in Q2 2013 and has held it in 26 quarters since. The position peaked at $551K in Q2 2014. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Group One Trading held 13,222 shares of Protalix BioTherapeutics worth $28.7K as of Q1 2026.
  • Protalix BioTherapeutics was a new Group One Trading position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5703 holding.
  • Group One Trading first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 26 quarters since.
  • Group One Trading's Protalix BioTherapeutics position peaked at $551K in Q2 2014.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.